Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor Conference taking place on Tuesday October 17, 2023. As part of the presentation, Melisa Tosca, CPA, Kiora's Executive Vice President of Finance, will provide an overview of the Company's business and clinical development pipeline for inherited retinal diseases.
The presentation is accessible on-demand starting at 7:00 am on the day of the conference and can be viewed by clicking here (https://wsw.com/webcast/lytham9/kprx/2075592 ) or by visiting the Investor Relations section of Kiora's website at ir.kiorapharma.com. Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at firstname.lastname@example.org or register at https://www.lythampartners.com/fall2023invreg/.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of Retinitis Pigmentosa, and Kiora also plans to develop KIO-301 for Choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. Kiora also plans to develop KIO-104 for the treatment of posterior non-infectious uveitis. This small molecule is a next-generation, non-steroidal, immuno-modulatory Dihydroorotate Dehydrogenase (DHODH) inhibitor with what Kiora believes is best-in-class potency.
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-301 and KIO-104, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, and Kiora's ability to reach a quorum at the adjourned Special Meeting. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, the ability to obtain any required regulatory approvals, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023, or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/183923
SOURCE Kiora Pharmaceuticals, Inc.
Released October 16, 2023